Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 35Gastrointestinal 27Thoracic 25Other hematologic neoplasm 24Genitourinary 21Other solid neoplasm 17Head & Neck 16Gynecologic 13Tumor-Agnostic 10Lymphoid 9Dermatologic 6CNS 6Plasma cell 5Sarcoma 3Myeloid 3Other 2Other neoplasm 1Endocrine 1Classical hematology 1

Conditions

Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Practice Guidelines as Topic × Endocrine × Clear all
NCT04032106 2025-03-14

HPV Vaccine Intervention for Young Sexual Minority Men

Ohio State University Comprehensive Cancer Center

Phase NA Completed
1,227 enrolled 8 charts
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡